Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
نویسندگان
چکیده
منابع مشابه
Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
INTRODUCTION Regorafenib was recently approved for patients with pretreated advanced colorectal cancer (aCRC), despite a moderate improvement of the patients' outcome, and significant toxicities. Based on previous studies showing that early fluorodeoxyglucose-positron emission tomography (FDG-PET)-based metabolic response assessment (MRA) might adequately select patients unlikely to benefit fro...
متن کاملRegorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
PURPOSE Regorafenib, an oral multi-targeted tyrosine kinase inhibitor, is considered the new standard of care in patients with chemotherapy-refractory colorectal cancers (CRCs). However, there are no data on this drug in Korean patients. MATERIALS AND METHODS We evaluated patients who received oral regorafenib 160 mg once daily during the first 3 weeks of each 4-week cycle between August 2013...
متن کاملTowards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
Blocking angiogenesis has been shown to boost biological activity of antineoplastic agents in the treatment of metastatic colorectal cancer (mCRC). Combinations of chemotherapy backbones with antiangiogenic antibody constructs with a double antineoplastic and antiangiogenic spectrum of action are in routine clinical practice of mCRC Regorafenib is an oral tyrosine kinase inhibitor (TKI) that ta...
متن کاملClinical management of regorafenib in the treatment of patients with advanced colorectal cancer
Colorectal cancer is one of the most common tumors worldwide and at least 50 % of patients with this disease develop metastases. In this setting, additional treatment options are needed for patients presenting disease progression after exhausting all standard therapies. Regorafenib is an orally administered multikinase inhibitor which has been shown to provide survival benefits to patients with...
متن کاملSHP-1 is a target of regorafenib in colorectal cancer
Regorafenib is an inhibitor of multiple protein kinases which exerts antitumor and antimetastatic activities in metastatic colorectal cancer (CRC). SH2 domain-containing phosphatase 1 (SHP-1) is reported to have tumor suppressive potential because it acts as a negative regulator of p-STAT3(Tyr705) signaling. However, little is known about the mechanism regarding regorafenib affects SHP-1 tyrosi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ Open
سال: 2015
ISSN: 2044-6055
DOI: 10.1136/bmjopen-2014-007189